NCT04255238View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

PHASE3UnknownINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

May 30, 2022

Study Completion Date

December 30, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Gemigliptin 50mg

The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day

DRUG

Dapagliflozin 10mg

The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04255238 - A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone | Biotech Hunter | Biotech Hunter